The Zhitong Finance App learned that the biopharmaceutical company NuVox Therapeutics (NUOX.US), which is in the second phase of clinical trials, submitted an initial public offering (IPO) application to the US Securities and Exchange Commission (SEC) last Friday, and plans to raise up to 20 million US dollars. The company focuses on developing oxygen therapy drugs aimed at improving tissue hypoxia.
According to the prospectus, NuVox plans to issue 2.9 million shares, with an issue price range of 6 to 8 US dollars per share. Based on the median value of the distribution range, the company's fully diluted market value is approximately US$98 million.
NuVox Therapeutics is a clinical-stage biopharmaceutical company. The core line NaNO2 is a dodecafluoropentane-based intravenous oxygen therapy drug targeting the field of diseases that cause morbidity or death due to tissue hypoxia. Currently, the company's leading indications are acute ischemic stroke and glioblastoma. Nano2 has completed phase IB/IIa trials and is currently undergoing phase IIb research. Among them, clinical trials initiated by researchers in the UK are ongoing for stroke indications. In addition, the company is also developing acute respiratory distress syndrome (ARDS) and sickle cell anemia in the early stages, which were approved by the FDA as orphan drugs in 2016 (glioblastoma obtained in 2015). Currently, NaNO2 has not received any regulatory approval, and no pharmacological treatment has been approved for acute ischemic stroke, glioblastoma, or ARDS-related hypoxia.
NuVox Therapeutics, headquartered in Tucson, Arizona, was founded in 2008 and has achieved $1 million in revenue over the past 12 months ending March 31, 2026. The company plans to be listed on the NYSE American Board (NYSE American) under the stock code “NUOX.” The company submitted the application confidentially on December 23, 2024. The sole bookkeeper for this release is ThinkEquity.